Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not Talpher, Inc.) on January 8, 2017. The report discloses financial information regarding cash and loan balances as of December 31, 2016, intended for use in investor meetings at the J.P. Morgan Healthcare Conference and The Trout Group Annual 1x1 Management Access Event in San Francisco.
Key Financial Metrics
The filing references specific financial data (cash and outstanding loan balances as of December 31, 2016) located in Exhibit 99.1 (slides #36 and #39 of the presentation handout). The text of this 8-K does not explicitly state the numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are incorporated by reference but not detailed in the body of this report.
Material Changes and Corporate Announcements
- Brand Name Announcement: The Company announced that DSUVIA is the brand name for its drug candidate ARX-04 in the United States.
- Therapeutic Indication: DSUVIA is intended for the treatment of moderate-to-severe acute pain.
- Guidance: The Company provided guidance on 2017 milestones for DSUVIA (Exhibit 99.3).
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding 2017 milestones for DSUVIA. The presentation handout (Exhibit 99.1) contains cautionary language intended to qualify these forward-looking statements. The financial information and presentation materials are deemed "furnished" rather than "filed" and are not subject to the liabilities of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
Investor Verification Checklist
- Review Exhibit 99.1 (slides #36 and #39) for the specific cash and loan balance figures as of December 31, 2016, which are not listed in the main text.
- Examine Exhibit 99.3 for the detailed 2017 milestones and guidance for DSUVIA.
- Verify the regulatory status and development timeline for DSUVIA (formerly ARX-04) for acute pain treatment.
- Note that the financial data in this filing is not incorporated by reference into future SEC filings.